Methods for diagnosis of bile acid malabsorption in clinical practice

Priya Vijayvargiya, Michael Camilleri, Andrea Shin, Amy Saenger

Research output: Contribution to journalReview article

55 Citations (Scopus)

Abstract

Altered concentrations of bile acid (BA) in the colon can cause diarrhea or constipation. More than 25% of patients with irritable bowel syndrome with diarrhea or chronic diarrhea in Western countries have BA malabsorption (BAM). As BAM is increasingly recognized, proper diagnostic methods are needed to help direct the most effective course of treatment for the chronic bowel dysfunction. We review the methodologies, advantages, and disadvantages oftools that directly measure BAM: the 14C-glycocholate breath and stool test, the 75selenium homotaurocholic acid test (SeHCAT), and measurements of 7 α-hydroxy-4-cholesten-3-one (C4) and fecal BAs. The 14C-glycocholate test is laborious and no longer widely used. The 75SeHCAT has been validated but is not available in the United States. Measurement of serum C4 is a simple and accurate method that can be used for most patients but requires further clinical validation. Assays to quantify fecal BA (total and individual levels) are technically cumbersome and not widely available. Regrettably, none of these tests are routinely available in the United States; assessment of the therapeutic effects of a BA binder is used as a surrogate for diagnosis of BAM. Recent data indicate the advantages to studying fecal excretion of individual BAs and their role in BAM; these could support the use of the fecal BA assay, compared with other tests. Measurement of fecal BA levels could become a routine addition to the measurement of fecal fat in patients with unexplained diarrhea. Availability ultimately determines whether the C4, SeHCAT, or fecal BA test is used; more widespread availability of such tests would enhance clinical management of these patients.

Original languageEnglish (US)
Pages (from-to)1232-1239
Number of pages8
JournalClinical Gastroenterology and Hepatology
Volume11
Issue number10
DOIs
StatePublished - Oct 2013
Externally publishedYes

Fingerprint

Bile Acids and Salts
Diarrhea
Glycocholic Acid
Breath Tests
Irritable Bowel Syndrome
Therapeutic Uses
Constipation
Colon
Fats
Acids
Serum

Keywords

  • C4
  • Diarrhea
  • Fecal
  • Glycocholate
  • SeHCAT

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Methods for diagnosis of bile acid malabsorption in clinical practice. / Vijayvargiya, Priya; Camilleri, Michael; Shin, Andrea; Saenger, Amy.

In: Clinical Gastroenterology and Hepatology, Vol. 11, No. 10, 10.2013, p. 1232-1239.

Research output: Contribution to journalReview article

Vijayvargiya, Priya ; Camilleri, Michael ; Shin, Andrea ; Saenger, Amy. / Methods for diagnosis of bile acid malabsorption in clinical practice. In: Clinical Gastroenterology and Hepatology. 2013 ; Vol. 11, No. 10. pp. 1232-1239.
@article{b536add0b19b453f88e723ae27daac01,
title = "Methods for diagnosis of bile acid malabsorption in clinical practice",
abstract = "Altered concentrations of bile acid (BA) in the colon can cause diarrhea or constipation. More than 25{\%} of patients with irritable bowel syndrome with diarrhea or chronic diarrhea in Western countries have BA malabsorption (BAM). As BAM is increasingly recognized, proper diagnostic methods are needed to help direct the most effective course of treatment for the chronic bowel dysfunction. We review the methodologies, advantages, and disadvantages oftools that directly measure BAM: the 14C-glycocholate breath and stool test, the 75selenium homotaurocholic acid test (SeHCAT), and measurements of 7 α-hydroxy-4-cholesten-3-one (C4) and fecal BAs. The 14C-glycocholate test is laborious and no longer widely used. The 75SeHCAT has been validated but is not available in the United States. Measurement of serum C4 is a simple and accurate method that can be used for most patients but requires further clinical validation. Assays to quantify fecal BA (total and individual levels) are technically cumbersome and not widely available. Regrettably, none of these tests are routinely available in the United States; assessment of the therapeutic effects of a BA binder is used as a surrogate for diagnosis of BAM. Recent data indicate the advantages to studying fecal excretion of individual BAs and their role in BAM; these could support the use of the fecal BA assay, compared with other tests. Measurement of fecal BA levels could become a routine addition to the measurement of fecal fat in patients with unexplained diarrhea. Availability ultimately determines whether the C4, SeHCAT, or fecal BA test is used; more widespread availability of such tests would enhance clinical management of these patients.",
keywords = "C4, Diarrhea, Fecal, Glycocholate, SeHCAT",
author = "Priya Vijayvargiya and Michael Camilleri and Andrea Shin and Amy Saenger",
year = "2013",
month = "10",
doi = "10.1016/j.cgh.2013.04.029",
language = "English (US)",
volume = "11",
pages = "1232--1239",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Methods for diagnosis of bile acid malabsorption in clinical practice

AU - Vijayvargiya, Priya

AU - Camilleri, Michael

AU - Shin, Andrea

AU - Saenger, Amy

PY - 2013/10

Y1 - 2013/10

N2 - Altered concentrations of bile acid (BA) in the colon can cause diarrhea or constipation. More than 25% of patients with irritable bowel syndrome with diarrhea or chronic diarrhea in Western countries have BA malabsorption (BAM). As BAM is increasingly recognized, proper diagnostic methods are needed to help direct the most effective course of treatment for the chronic bowel dysfunction. We review the methodologies, advantages, and disadvantages oftools that directly measure BAM: the 14C-glycocholate breath and stool test, the 75selenium homotaurocholic acid test (SeHCAT), and measurements of 7 α-hydroxy-4-cholesten-3-one (C4) and fecal BAs. The 14C-glycocholate test is laborious and no longer widely used. The 75SeHCAT has been validated but is not available in the United States. Measurement of serum C4 is a simple and accurate method that can be used for most patients but requires further clinical validation. Assays to quantify fecal BA (total and individual levels) are technically cumbersome and not widely available. Regrettably, none of these tests are routinely available in the United States; assessment of the therapeutic effects of a BA binder is used as a surrogate for diagnosis of BAM. Recent data indicate the advantages to studying fecal excretion of individual BAs and their role in BAM; these could support the use of the fecal BA assay, compared with other tests. Measurement of fecal BA levels could become a routine addition to the measurement of fecal fat in patients with unexplained diarrhea. Availability ultimately determines whether the C4, SeHCAT, or fecal BA test is used; more widespread availability of such tests would enhance clinical management of these patients.

AB - Altered concentrations of bile acid (BA) in the colon can cause diarrhea or constipation. More than 25% of patients with irritable bowel syndrome with diarrhea or chronic diarrhea in Western countries have BA malabsorption (BAM). As BAM is increasingly recognized, proper diagnostic methods are needed to help direct the most effective course of treatment for the chronic bowel dysfunction. We review the methodologies, advantages, and disadvantages oftools that directly measure BAM: the 14C-glycocholate breath and stool test, the 75selenium homotaurocholic acid test (SeHCAT), and measurements of 7 α-hydroxy-4-cholesten-3-one (C4) and fecal BAs. The 14C-glycocholate test is laborious and no longer widely used. The 75SeHCAT has been validated but is not available in the United States. Measurement of serum C4 is a simple and accurate method that can be used for most patients but requires further clinical validation. Assays to quantify fecal BA (total and individual levels) are technically cumbersome and not widely available. Regrettably, none of these tests are routinely available in the United States; assessment of the therapeutic effects of a BA binder is used as a surrogate for diagnosis of BAM. Recent data indicate the advantages to studying fecal excretion of individual BAs and their role in BAM; these could support the use of the fecal BA assay, compared with other tests. Measurement of fecal BA levels could become a routine addition to the measurement of fecal fat in patients with unexplained diarrhea. Availability ultimately determines whether the C4, SeHCAT, or fecal BA test is used; more widespread availability of such tests would enhance clinical management of these patients.

KW - C4

KW - Diarrhea

KW - Fecal

KW - Glycocholate

KW - SeHCAT

UR - http://www.scopus.com/inward/record.url?scp=84884354833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884354833&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2013.04.029

DO - 10.1016/j.cgh.2013.04.029

M3 - Review article

VL - 11

SP - 1232

EP - 1239

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 10

ER -